Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 17, 2021 08:00 ET | Source: Oncocyte Corporation

Oncocyte Launches First Real-World Evidence (RWE) Registry to Evaluate Biomarker Impact on Early-Stage Lung Cancer Treatment Decisions and Outcomes

Predictive Assay for Decision Making in Adjuvant Therapy (PADMA) Registry to enroll more than 1,000 patients at 25 major hospitals treating lung cancer in the United States beginning Q4 2021 ...
August 10, 2021 16:01 ET | Source: Oncocyte Corporation

Oncocyte Reports Second Quarter 2021 Financial Results and Provides Corporate Update

DetermaRx Q2 Sample Volume Grows 23% over Q1 2021 Potential pan-cancer utility of DetermaIO strengthened by data in breast, lung, bladder and renal cell cancer, validating the test in all four tumor...
August 09, 2021 08:00 ET | Source: Oncocyte Corporation

Oncocyte to Participate in Upcoming Investor Events

IRVINE, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
July 27, 2021 10:35 ET | Source: Oncocyte Corporation

Oncocyte to Report Second Quarter 2021 Financial Results on Tuesday, August 10

IRVINE, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
June 22, 2021 08:00 ET | Source: Oncocyte Corporation

Oncocyte Celebrates Women Thoracic Surgeons in #ShesMySurgeon Campaign

IRVINE, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
June 03, 2021 08:00 ET | Source: Oncocyte Corporation

Oncocyte Announces Collaboration with Gruppo Oncologico del Nord Ovest to Evaluate Oncocyte’s DetermaIO Test in Colorectal Cancer, the Second Leading Cause of Cancer Mortality Globally

Gruppo Oncologico del Nord Ovest, a Leading European Clinical Trials Group, Conducts Independent Investigator-Sponsored Clinical Trials for Pharmaceutical Targeted and Immune Therapies If...
June 01, 2021 08:00 ET | Source: Oncocyte Corporation

Oncocyte Selected as New “Day One” Launch Site for QIAGEN’s Companion Diagnostics Test to Identify Patients for Amgen’s Newly FDA-Approved Drug LUMAKRAS (Sotorasib) For Advanced Stage Lung Cancer

Oncocyte’s Nashville CLIA lab now offers the Therascreen RGQ KRAS test Addition of the Therascreen RGQ KRAS test strengthens Oncocyte’s one-stop shop offering for lung cancer treatment decisions ...
May 17, 2021 16:01 ET | Source: Oncocyte Corporation

Oncocyte Reports First Quarter 2021 Financial Results and Provides Corporate Update

-Oncocyte Q1 revenues beat consensus estimate, driven by strong DetermaRx and Pharma Services growth - -Data in four indications (TNBC, NSCLC, bladder, and renal cell cancer) suggest pan-cancer...
May 06, 2021 08:00 ET | Source: Oncocyte Corporation

Medicare Coverage Determination for Molecular Testing Announced for Solid Organ Allograft Rejection, Citing Multiple Publications from OncoCyte Corporation’s Subsidiary Chronix Biomedical, Inc.

Coverage policy for transplant rejection monitoring establishes a simplified and accelerated pathway for Medicare coverage of Chronix’s solid organ transplant rejection monitoring test Oncocyte’s...
May 04, 2021 16:01 ET | Source: Oncocyte Corporation

Oncocyte to Report First Quarter 2021 Financial Results on Monday, May 17

IRVINE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...